NASDAQ:SNY 15 December 2025

Sanofi Stock (SAN.PA, SNY) Slides After Tolebrutinib Double Setback: FDA Delay, Trial Miss, and Fresh Analyst Forecasts (Dec. 15, 2025)

Sanofi shares fell about 4% in Paris on December 15 after the company reported a U.S. regulatory delay for tolebrutinib in non-relapsing secondary progressive MS and a failed Phase 3 trial in primary progressive MS. Sanofi will not seek approval for the latter indication. The FDA decision for nrSPMS is now expected after December 28, with further guidance by end of Q1 2026.

15 December 2025

EPA:SAN.PA·NASDAQ:SNY·Pharmaceuticals·Stock Market

Union Pacific Stock Seen Undervalued Amid Recent Price Drop
March 20, 2026, 2:10 PM EDT. Union Pacific (ticker: UNP) shares dropped roughly 11% over the past month, now trading near $234. Despite this short-term weakness, the railroad operator maintains positive returns of 1% year-to-date and over 20% across five years. A discounted cash flow (DCF) analysis estimates an intrinsic value around $313 per share, indicating the stock trades about 25% below its cash flow-based valuation, suggesting undervaluation. The price-to-earnings (P/E) metric offers another lens but is secondary to DCF in this review. Investors should weigh recent volatility against Union Pacific's strong long-term fundamentals and sector dynamics before deciding whether current weakness presents a buying opportunity.